U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline ...

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced on Monday that its experimental drug, when combined with Novo ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 million upfront for a preclinical GLP-1 drug the company hopes will have a ...

A Phase 3 trial in obesity in China and Phase 2b study in diabetes ... will allow us to study combinations with Regeneron’s proprietary drugs and drug candidates in order to holistically address ...

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China Phase 2 data suggest potentially similar ...

Amgen and Regeneron. Also, a draft bill in Congress would restrict U.S. involvement with Chinese biotechs. Amgen wants to create an obesity drug that patients can wean over time instead of being ...